Related Experiment Video
Updated: Feb 8, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia
Forest W Arnold1, Gustavo Lopardo2, Timothy L Wiemken1
1Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Louisville, Louisville, KY, United States.
Background:
Community-acquired pneumonia (CAP) has a potential complication of bacteremia. The objective of this study was to define the clinical outcomes of patients with CAP and bacteremia treated with and without a macrolide.
Materials And Methods:
Secondary analysis of the Community-Acquired Pneumonia Organization database of hospitalized patients with CAP. Patients with a positive blood culture were categorized based on the presence or absence of a macrolide in their initial antimicrobial regimen, and severity of their CAP. Outcomes included in-hospital all-cause mortality, 30-day mortality, length of stay, and time to clinical stability.
Results:
Among 549 patients with CAP and bacteremia, 247 (45%) were treated with a macrolide and 302 (55%) were not. The primary pathogen was Streptococcus pneumoniae (74%). Poisson regression with robust error variance models were used to compare the adjusted effects of each study group on the outcomes. The unadjusted 30-day mortality was 18.4% in the macrolide group, and 29.6% in the non-macrolide group (adjusted relative risk (aRR)0.81; 95% confidence interval (CI)0.50-1.33; P = 0.41). Unadjusted in-hospital all-cause mortality was 7.3% in the macrolide group, and 18.9% in the non-macrolide group (aRR 0.54, 95% CI 0.30-0.98; P = 0.043). Length of stay and time to clinical stability were not significantly different.
Conclusions:
In-hospital mortality, but not 30-day mortality, was significantly better in the macrolide group. Our data support the use of a macrolide in hospitalized patients with CAP and bacteraemia.
Insights
Macrolide antibiotics significantly reduced in-hospital mortality for patients with community-acquired pneumonia (CAP) and bacteremia. This finding supports macrolide use in hospitalized CAP patients with bloodstream infections.
Area of Science:
- Infectious Diseases
- Clinical Medicine
- Pharmacology
Background:
- Community-acquired pneumonia (CAP) can lead to bacteremia.
- Understanding the impact of macrolide treatment on CAP with bacteremia is crucial for clinical practice.
Purpose of the Study:
- To compare clinical outcomes in patients with CAP and bacteremia treated with or without macrolides.
- To evaluate the efficacy of macrolides in reducing mortality and improving other outcomes in this patient population.
Main Methods:
- Secondary analysis of the Community-Acquired Pneumonia Organization database.
- Patients with CAP and positive blood cultures were grouped based on macrolide use in initial antimicrobial therapy.
- Outcomes assessed included in-hospital mortality, 30-day mortality, length of stay, and time to clinical stability.
Main Results:
- Of 549 patients with CAP and bacteremia, 45% received macrolides.
- In-hospital mortality was significantly lower in the macrolide group (7.3% vs. 18.9%, adjusted RR 0.54).
- 30-day mortality, length of stay, and time to clinical stability did not differ significantly between groups.
Conclusions:
- Macrolide treatment was associated with significantly reduced in-hospital mortality in patients with CAP and bacteremia.
- The findings support the use of macrolides for hospitalized patients diagnosed with CAP and bacteremia.
- Further research may explore specific macrolide benefits in subgroups.
Related Concept Videos
What are Populations and Communities?
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Community Based Intervention
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
Gene Therapy

